Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise: A randomized, double-blind, placebo-controlled, phase 3 trial

Documenti analoghi

• Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
  di: Bailey, Clifford J, et al.
  Pubblicazione: (2013)
• Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA(1c), Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
  di: Rosenstock, Julio, et al.
  Pubblicazione: (2012)
• Correction: Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
  di: Bailey, Clifford J, et al.
  Pubblicazione: (2013)
• Phase III, randomized, double‐blind, placebo‐controlled study to evaluate the efficacy and safety of teneligliptin monotherapy in Chinese patients with type 2 diabetes mellitus inadequately controlled with diet and exercise
  di: Ji, Linong, et al.
  Pubblicazione: (2020)
• Double‐blind, placebo‐controlled study of lurasidone monotherapy for the treatment of bipolar I depression
  di: Kato, Tadafumi, et al.
  Pubblicazione: (2020)